Information about ExpressMedsCanada.to
List of countries where we can ship Descovy:
Latest news releases on Descovy:
Learn more about DESCOVY® (emtricitabine and tenofovir alafenamide). Read important safety information and warnings.
DESCOVY® (FTC/TAF) is a dual-NRTI backbone, which is an essential element of a complete HIV-1 regimen. 1,2. DESCOVY is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients weighing at least 35 kg.
What form(s) does this medication come in? 200 mg/10 mg Each rectangular, film-coated grey tablet debossed “GSI” on one side and “210” on the other contains 200 mg of emtricitabine and 10 mg of tenofovir alafenamide.
U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
1 Descovy 200/10 mg in combination with darunavir 800 mg and cobicistat 150 mg, administered as a fixed-dose combination tablet, was studied in treatment- naive subjects, see section 5.1.
Gleichzeitig mit Rifampicin, Rifabutin, Rifapentin, Johanniskraut. Fortpflanzung bei der Frau, Stillzeit.
The U.S. Food and Drug Administration this week approved Descovy, Gilead Sciences’ latest combination pill containing emtricitabine and an updated version of tenofovir.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Find information about dosing for BIKTARVY® (bictegravir, emtricitabine, tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV-1 in certain adults. Read full Prescribing Information, including BOXED WARNING.